Adnexus Therapeutics

Acquired

Adnexus Therapeutics is a biotech company in Waltham, United States, founded in 2003. It has raised $42.5M across 2 rounds, most recently a $15.5M Series C in August 2007.

Pioneering Adnectin therapeutics based on human fibronectin.

Employees
1–10
Founded
2003
Business Model
B2B
Total Funding
$42.5M
Last Round
$15.5M Series CAug 2007
Rounds
2
Acquired by
Bristol-Myers Squibb CompanySep 2007 · $430.0M

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

Indexed holds 2 funding rounds and 9 investors for this company. The full record is or through the API.

About

Adnexus Therapeutics, founded in 2003 and headquartered in Waltham, Massachusetts, was a biopharmaceutical company that pioneered Adnectin therapeutics — engineered variants of the tenth type III domain of human fibronectin. Adnectins were designed as a new protein scaffold platform to generate highly potent, specific, and stable therapeutic agents with favorable half-life and high-yield E. coli production. The company's lead oncology compound, CT-322, was an Adnectin inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) developed as an anti-angiogenic cancer therapy. Adnexus was founded by Flagship Pioneering (then Flagship Ventures) and acquired by Bristol-Myers Squibb in September 2007 for approximately $430 million, making it one of the largest biotech acquisitions of that year.

Summary

It lists 1–10 employees. It has raised $42.5M in total across 2 rounds, most recently a $15.5M Series C round in Aug 2007. Investors include Bristol Myers Squibb, HBM BioVentures and Venrock.

Funding & Exit History

Data from Indexed.vcUpdated
AcquisitionAcquisition by Bristol-Myers SquibbSep 2007

Sign up to see all 3 events

Funding: Series B through Series C. Amounts, valuations, and investors where available.

Investors

Similar Companies

Tiantan Biological / China Biologic (泰邦生物集团)

China's leading blood products manufacturer

Beijing, China1001–5000Biotech, Healthcare
Growth EquityTotal funding$5.1BAug 2022
Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Adnexus Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/adnexus-therapeutics"><img src="https://indexed.vc/api/badge/company/adnexus-therapeutics" alt="Adnexus Therapeutics on Indexed.vc" width="260" height="76" /></a>